Biomea's Oral GLP-1 BMF-650 Shows Up to 6.1% Weight Loss in Phase 1, Plans Partnership
BMEA sits 33% above its 52-week low of $0.872 on elevated volume (3.0× avg).
Summary
Biomea Fusion reported Phase 1 results for BMF-650, its oral GLP-1 receptor agonist, showing consistent weight reduction across five dose cohorts. In Cohorts 1-4, mean Day 29 weight loss ranged from 1.5% to 3.2% versus 0.1% for placebo. The fifth cohort, using a rapid one-step titration to 400 mg, achieved 6.1% mean weight loss (6.2 kg) over four weeks, though placebo patients in that confined setting also lost weight, complicating interpretation. Tolerability was encouraging: no severe or serious adverse events, and GI side effects were mild. The company plans to seek a strategic partnership for late-stage development while focusing internally on icovamenib for diabetes. This is the first detailed efficacy data for BMF-650 and validates the molecule's design goal of reducing GI side effects while maintaining weight loss. The stock is a micro-cap ($91M), so positive clinical data could drive significant volatility. Next steps include longer-term toxicology studies and potential licensing discussions.
Updates
· Wiseek News — Biomea will run longer toxicology studies for BMF-650 and continues icovamenib diabetes work with ongoing data analysis.
At the time of this announcement, BMEA was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.3M. The 52-week trading range was $0.87 to $2.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.